After having a little research on CRL
from FDA . It appears there are 2 categories
1 is a two month assessment
2 is a six month assessment.
The majority of approval failures are to do
with efficacy and safety not manufacturing etc.
Since this will be Maynes 3rd resubmission
mine would think they would have learnt.
Just because the FDA don’t raise issues
with them doesn’t mean they are ok in that
area. Obviously like giving the answers to
questions prior to the exam.
I wish Mayne would stop repeating how they
are working closely with FDA.
They along with Mithra are gaining a reputation
as Pharmaceutical Nincompoops ..
- Forums
- ASX - By Stock
- Ann: MAYNE PHARMA provides FDA update on generic NUVARING
MYX
mayne pharma group limited
Add to My Watchlist
1.63%
!
$5.00

After having a little research on CRLfrom FDA . It appears there...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.00 |
Change
0.080(1.63%) |
Mkt cap ! $406.2M |
Open | High | Low | Value | Volume |
$4.93 | $5.10 | $4.93 | $3.062M | 610.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 67102 | $5.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.05 | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 67102 | 5.000 |
1 | 4000 | 4.990 |
1 | 5000 | 4.930 |
1 | 5000 | 4.860 |
3 | 1410 | 4.850 |
Price($) | Vol. | No. |
---|---|---|
5.050 | 5000 | 1 |
5.100 | 584 | 1 |
5.120 | 2000 | 1 |
5.130 | 600 | 1 |
5.140 | 4323 | 3 |
Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |